What is HC Wainwright’s Estimate for CRNX Q2 Earnings?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) – Investment analysts at HC Wainwright decreased their Q2 2026 earnings per share estimates for shares of Crinetics Pharmaceuticals in a report released on Friday, May 8th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($1.28) per share for the quarter, down from their previous estimate of ($1.19). The consensus estimate for Crinetics Pharmaceuticals’ current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Crinetics Pharmaceuticals’ Q3 2026 earnings at ($1.27) EPS, Q4 2026 earnings at ($1.25) EPS, FY2026 earnings at ($5.03) EPS, FY2027 earnings at ($4.68) EPS, FY2028 earnings at ($3.72) EPS and FY2029 earnings at ($1.06) EPS.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.01). Crinetics Pharmaceuticals had a negative return on equity of 43.96% and a negative net margin of 2,747.18%.The business had revenue of $10.73 million for the quarter, compared to analyst estimates of $8.51 million. During the same period in the prior year, the firm posted ($1.04) EPS. Crinetics Pharmaceuticals’s revenue for the quarter was up 2873.4% on a year-over-year basis.

Several other equities analysts have also recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research report on Monday, April 20th. Wall Street Zen cut Crinetics Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. The Goldman Sachs Group raised Crinetics Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $67.00 price objective for the company in a research report on Monday, January 12th. Lifesci Capital raised Crinetics Pharmaceuticals to a “strong-buy” rating in a research report on Friday, February 13th. Finally, Oppenheimer cut their price objective on Crinetics Pharmaceuticals from $87.00 to $84.00 and set an “outperform” rating for the company in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $76.13.

Crinetics Pharmaceuticals Stock Performance

NASDAQ CRNX opened at $36.55 on Tuesday. Crinetics Pharmaceuticals has a twelve month low of $25.83 and a twelve month high of $57.99. The stock has a market capitalization of $3.85 billion, a PE ratio of -7.12 and a beta of 0.28. The stock has a 50-day simple moving average of $38.14 and a 200 day simple moving average of $43.81.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its holdings in Crinetics Pharmaceuticals by 55.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 852,258 shares of the company’s stock valued at $30,935,000 after acquiring an additional 303,281 shares in the last quarter. SEB Asset Management AB acquired a new position in Crinetics Pharmaceuticals in the 1st quarter valued at approximately $7,769,000. Principal Financial Group Inc. raised its holdings in Crinetics Pharmaceuticals by 32.3% in the 1st quarter. Principal Financial Group Inc. now owns 7,066 shares of the company’s stock valued at $257,000 after acquiring an additional 1,725 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its holdings in shares of Crinetics Pharmaceuticals by 4.0% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 28,477 shares of the company’s stock worth $1,034,000 after buying an additional 1,100 shares in the last quarter. Finally, Fifth Third Bancorp acquired a new position in shares of Crinetics Pharmaceuticals in the 1st quarter worth approximately $126,000. Institutional investors and hedge funds own 98.51% of the company’s stock.

Insider Transactions at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, insider Stephen F. Betz sold 10,612 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $37.37, for a total value of $396,570.44. Following the completion of the transaction, the insider owned 137,101 shares of the company’s stock, valued at $5,123,464.37. This represents a 7.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Richard Scott Struthers sold 21,981 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $37.37, for a total value of $821,429.97. Following the completion of the transaction, the chief executive officer directly owned 404,778 shares of the company’s stock, valued at approximately $15,126,553.86. This trade represents a 5.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 142,380 shares of company stock worth $5,569,475. 3.80% of the stock is currently owned by company insiders.

Key Headlines Impacting Crinetics Pharmaceuticals

Here are the key news stories impacting Crinetics Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital raised its Q2, Q3, and Q4 2026 EPS estimates for Crinetics Pharmaceuticals and kept a Strong-Buy rating, signaling improved near-term expectations. The firm also lifted its FY2026 EPS estimate from a larger loss to a somewhat smaller loss.
• Positive Sentiment: A Yahoo Finance-linked note said analysts are lifting estimates after Crinetics reported first-quarter earnings, suggesting the recent quarter may have reassured some investors about the company’s execution. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
• Neutral Sentiment: Oppenheimer cut its price target on Crinetics Pharmaceuticals to $84 from $87, but maintained an Outperform rating. This is still above the current trading level, yet the cut can weigh on sentiment. Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Cut to $84.00 by Analysts at Oppenheimer
• Neutral Sentiment: HC Wainwright trimmed multiple longer-term EPS estimates, including FY2026, FY2027, FY2028, and FY2029, reflecting a more conservative outlook beyond the next few quarters.
• Neutral Sentiment: Crinetics remains a loss-making biotech, with consensus FY2026 EPS still expected at a loss of $4.95 per share, so the stock is highly sensitive to changes in development and profitability expectations.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.